Hikal Reports Q2 FY27 Earnings with Strong Revenue and Operational Recovery
Hikal Ltd · Press Release · 03 Nov 2026, 9:27 pm
Hikal Reports Q2 FY27 Earnings with Strong Revenue and Operational Recovery Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY and 8% QoQ, driven by recovery in its API portfolio and sustained CDMO execution. Pharmaceuticals revenue rose 47% YoY to ₹278 crore, while Crop Protection grew 21% YoY to ₹156 crore. EBITDA jumped to ₹45 crore with a 10.3% margin, narrowing net loss to ₹6 crore from ₹35 crore YoY. The company signed a multi-year European agrochemical CDMO contract, secured Swissmedic approval, and reiterated mid-teens revenue growth guidance for FY27.
Original exchange filing (PDF)
More announcements from Hikal Ltd
- Transcript of Earnings Call for the Quarter and half year ended September 30, 2026. · 05 Nov 2026
- Audio Recording of Group Conference call for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Result presentation for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Pursuant to Regulation 30(5) of the SEBI LODR Regulations- List of KMP authorized to determine materiality and make disclosures. · 03 Nov 2026
- Unaudited Financial Results for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Hikal Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 03 Nov 2026
- Unaudited Financial Results for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Press Release on Hikal signs Multi-Year Global CDMO contract with leading Agrochemical Company · 02 Nov 2026
